140 related articles for article (PubMed ID: 7840599)
21. Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Nov; 38(11):2599-604. PubMed ID: 7872754
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility of anaerobic bacteria to PD 131628.
Nord CE; Hagelbäck A
Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):68-71. PubMed ID: 1314176
[TBL] [Abstract][Full Text] [Related]
23. Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a.
Morrissey I; Smith JT
J Med Microbiol; 1995 Jul; 43(1):4-8. PubMed ID: 7608954
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
Nord CE; Lindmark A; Persson I
Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
[TBL] [Abstract][Full Text] [Related]
25. Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci.
Forstall GJ; Knapp CC; Washington JA
Antimicrob Agents Chemother; 1994 Aug; 38(8):1868-70. PubMed ID: 7986024
[TBL] [Abstract][Full Text] [Related]
26. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
Goldstein EJ; Citron DM
Antimicrob Agents Chemother; 1992 May; 36(5):1158-62. PubMed ID: 1324640
[TBL] [Abstract][Full Text] [Related]
27. In vitro susceptibility of anaerobes to quinolones in the United States.
Hecht DW; Wexler HM
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
[TBL] [Abstract][Full Text] [Related]
28. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
Venezia RA; Yocum DM; Robbiano EM; Echols RM
Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.
García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García MI; Fresnadillo-Martínez MJ
J Chemother; 1995 Jun; 7(3):189-96. PubMed ID: 7562012
[TBL] [Abstract][Full Text] [Related]
30. Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.
Carlyn CJ; Doyle LJ; Knapp CC; Ludwig MD; Washington JA
Antimicrob Agents Chemother; 1995 Jul; 39(7):1606-8. PubMed ID: 7492114
[TBL] [Abstract][Full Text] [Related]
31. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.
Goldstein EJ
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S377-81. PubMed ID: 8324151
[TBL] [Abstract][Full Text] [Related]
32. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
Edlund C; Sabouri S; Nord CE
Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302
[TBL] [Abstract][Full Text] [Related]
33. Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.
Jones RN; Barrett MS; Biedenbach DJ
Diagn Microbiol Infect Dis; 1994 Jun; 19(2):93-9. PubMed ID: 7805362
[TBL] [Abstract][Full Text] [Related]
34. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.
Goldstein EJ; Citron DM; Hunt Gerardo S; Hudspeth M; Merriam CV
Antimicrob Agents Chemother; 1997 May; 41(5):1193-5. PubMed ID: 9145900
[TBL] [Abstract][Full Text] [Related]
35. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates.
Jones RN; Johnson DM; Biedenbach DJ; Marshall SA
Diagn Microbiol Infect Dis; 1995 Nov; 23(3):123-7. PubMed ID: 8849658
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
37. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.
Korten V; Tomayko JF; Murray BE
Antimicrob Agents Chemother; 1994 Mar; 38(3):611-5. PubMed ID: 8203863
[TBL] [Abstract][Full Text] [Related]
38. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
[TBL] [Abstract][Full Text] [Related]
39. Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media.
Hecht DW; Osmolski JR
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S44-50. PubMed ID: 8953106
[TBL] [Abstract][Full Text] [Related]
40. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
Spangler SK; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():23-7. PubMed ID: 9222066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
